Welcome to our dedicated page for Zevra Therapeutics news (Ticker: ZVRA), a resource for investors and traders seeking the latest updates and insights on Zevra Therapeutics stock.
Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) is a commercial-stage rare disease company whose news flow centers on its therapies for serious, low-prevalence conditions and the corporate developments that support these programs. The company regularly issues updates describing progress with its approved products, clinical pipeline, regulatory interactions, and financial performance.
A major theme in Zevra’s news is the commercialization and clinical evidence for MIPLYFFA (arimoclomol), its approved therapy for Niemann-Pick disease type C (NPC). Press releases highlight pivotal and long-term data, presentations at scientific and patient-focused meetings, and steps to broaden access, such as a distribution agreement with Uniphar to enable reimbursed named patient supply for NPC patients in select territories outside Europe. These items provide insight into how Zevra is working to expand the reach of its NPC treatment.
News coverage also includes updates on OLPRUVA (sodium phenylbutyrate), Zevra’s approved treatment for certain urea cycle disorders, and on celiprolol, its investigational candidate for vascular Ehlers-Danlos syndrome. The company reports on clinical trial enrollment milestones, publication of new analyses, and recognition of its scientific work at conferences, giving investors and clinicians visibility into the evolution of its rare disease portfolio.
In addition, Zevra issues quarterly financial results and corporate updates, detailing revenue contributions from its commercial products, operating expenses, and capital resources. Governance and organizational news, such as board appointments, executive transitions, and equity inducement grants under its employment inducement award plan, are disclosed through press releases and Form 8-K filings. For anyone tracking ZVRA, this news stream offers a consolidated view of the company’s therapeutic progress, regulatory status, and corporate trajectory in the rare disease space.
Zevra Therapeutics (NASDAQ:ZVRA) announced the publication of long-term efficacy data for MIPLYFFA® (arimoclomol) in treating Niemann-Pick disease type C (NPC) in the Molecular Genetics and Metabolism journal.
The open-label extension study demonstrated that MIPLYFFA maintains its ability to reduce disease progression for at least 5 years in NPC patients. The data encompasses safety and efficacy results from over 270 patients worldwide, with some patients receiving treatment for up to seven years. The results align with the previous Phase 2/3 trial showing MIPLYFFA's effectiveness in halting disease progression compared to placebo.
The study utilized the 5- and rescored 4-domain NPC Clinical Severity Scale, the only validated measurement of NPC progression, confirming sustained benefits with no new safety concerns.Zevra Therapeutics (NasdaqGS: ZVRA) announced that its FDA-approved treatment MIPLYFFA® (arimoclomol) will be featured in three presentations at the National Niemann Pick Disease Foundation Conference in July 2025. MIPLYFFA is the first FDA-approved treatment for Niemann-Pick disease type C (NPC), indicated for use with miglustat in patients 2 years and older.
The presentations include clinical data showing that MIPLYFFA, combined with miglustat, halted disease progression at 12 months in pivotal trials. Long-term data from a 48-month open-label extension confirmed the treatment's effectiveness and safety profile. Additional research demonstrated MIPLYFFA's mechanism of action through upregulation of CLEAR genes and improvement of lysosomal function.
Zevra Therapeutics (NASDAQ: ZVRA) announced the final results of its 2025 Annual Meeting of Stockholders, where shareholders overwhelmingly re-elected Wendy L. Dixon, Ph.D. and Tamara A. Favorito as Class I Directors to serve until 2028. The incumbent directors received approximately 74% of the votes, defeating potential opposition nominees Travis C. Mickle and Arthur C. Regan, who would have received only 26.45% and 23.97% respectively. The opposition nominations were ultimately disregarded due to failure to meet SEC and bylaw requirements. Stockholders also approved Ernst & Young LLP as the company's independent auditors for FY2025.
Zevra Therapeutics (ZVRA) reported strong Q1 2025 financial results with net revenue of $20.4 million, primarily driven by $17.1 million from MIPLYFFA sales. The company completed the sale of its Pediatric Rare Disease Priority Review Voucher for $150 million, significantly strengthening its balance sheet to $217 million in cash and equivalents.
Commercial progress includes 13 new MIPLYFFA prescriptions in Q1 (total 122) with 38% market access coverage, and 5 new OLPRUVA patients (total 28) with 78% market access. The company reported a reduced net loss of $3.1 million ($0.06 per share) compared to $16.6 million in Q1 2024. Operating expenses were $22.8 million, with R&D expenses decreasing by $9.0 million while SG&A increased by $9.6 million due to commercial activities.
The company remains on track for MIPLYFFA's European MAA filing in H2 2025 and has enrolled 32 patients in the Phase 3 DiSCOVER trial for celiprolol.Zevra Therapeutics (NASDAQ: ZVRA), a commercial-stage company focused on rare disease therapies, has scheduled its Q1 2025 financial results announcement for Tuesday, May 13, 2025. The company will release its corporate and financial results after market close, followed by a conference call and audio webcast at 4:30 p.m. ET.
Investors can access the webcast through Zevra's website investor relations section. For telephone participation, U.S. callers can dial (800) 245-3047, while international participants should use +1 (203) 518-9765, with Conference ID: ZVRAQ125. A replay will be available on the company's website for 90 days following the presentation.
Zevra Therapeutics (ZVRA), a commercial-stage rare disease therapeutics company, has announced its participation in the upcoming Citizens Life Science Conference in New York. The company's executive leadership team will engage in a fireside chat on Wednesday, May 7, 2025, at 11:30 a.m. ET. Management will also be available for one-on-one meetings with registered conference attendees. Investors can access the live webcast through the "Events & Presentations" section on Zevra's investor relations website at investors.zevra.com.
Zevra Therapeutics (ZVRA) has filed its definitive proxy statement for the 2025 Annual Meeting scheduled for May 29, urging stockholders to vote for two incumbent directors - Wendy L. Dixon and Tamara A. Favorito. The company highlights a 54.8% total stockholder return under its refreshed board and management team.
The Board strongly opposes attempts by Daniel J. Mangless, a 2.8% stockholder, to replace two directors. Mangless, who already has three nominees on the board from 2023, seeks to add two more nominees - Travis C. Mickle and Arthur C. Regan. The company argues this would give Mangless majority board control without presenting any clear strategic plans.
Under current leadership, Zevra has launched two rare disease therapies: MIPLYFFA® for Niemann-Pick disease type C, which earned a Priority Review Voucher sold for $150 million, and OLPRUVA® for urea cycle disorders. The company is executing a five-year strategic plan focused on commercial excellence, pipeline innovation, talent development, and corporate foundation strengthening.
Zevra Therapeutics (ZVRA) has published new research in Molecular Genetics and Metabolism detailing the mechanism of action of MIPLYFFA® in treating Niemann-Pick disease type C (NPC). The study reveals that arimoclomol enters cells and increases the movement of translation factors EB and E3 (TFEB & TFE3) from cytosol to nucleus.
This process triggers the upregulation of CLEAR genes, including NPC1, which is important for lysosomal function. The increased CLEAR gene expression leads to higher NPC1 protein levels in lysosomes, resulting in improved cholesterol trafficking. Animal studies demonstrated that this improved trafficking correlates with better neurological behaviors, specifically in rearing and gait.
Zevra Therapeutics (ZVRA) has completed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million in gross proceeds. The PRV was granted by the FDA in September 2024 following the approval of MIPLYFFA™ (arimoclomol), the first U.S. approved treatment for Niemann-Pick type C, an ultra-rare neurodegenerative disease.
The company reported unaudited cash, cash equivalents and investments of $68.7 million as of March 31, 2025. After the PRV sale's net proceeds of $148.3 million, the total cash position would be $217.0 million. The non-dilutive capital will support strategic priorities including the commercial launches of MIPLYFFA and OLPRUVA®, ongoing Phase 3 trial for celiprolol, and future strategic investments.
Zevra Therapeutics (NASDAQ: ZVRA) has filed its preliminary proxy statement for the 2025 Annual Meeting, nominating two directors for re-election: Wendy L. Dixon and Tamara A. Favorito. The company faces a proxy contest from stockholder Daniel J. Mangless, who proposes two alternative candidates.
The current board comprises eight directors, with seven being independent and seven joining since 2023. The company reports significant progress, including:
- Launch of first two products
- Record net product revenue in Q4 2024
- Cash runway extending into 2029
- Recent sale of Priority Review Voucher for $150 million
The board recommends stockholders reject Mangless's nominees, including former CEO Travis C. Mickle, arguing that changes could disrupt the company's strategic execution. Stockholders are advised to wait for the definitive proxy materials with the WHITE proxy card before taking any action.